Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Operating Leases (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Operating Leases data on record, last reported at $30.8 million in Q4 2025.

  • For Q4 2025, Operating Leases fell 9.42% year-over-year to $30.8 million; the TTM value through Dec 2025 reached $30.8 million, down 9.42%, while the annual FY2025 figure was $30.8 million, 9.42% down from the prior year.
  • Operating Leases reached $30.8 million in Q4 2025 per TNGX's latest filing, down from $31.7 million in the prior quarter.
  • Across five years, Operating Leases topped out at $39.9 million in Q3 2022 and bottomed at $6.1 million in Q3 2021.
  • Average Operating Leases over 5 years is $33.7 million, with a median of $35.5 million recorded in 2024.
  • Peak YoY movement for Operating Leases: skyrocketed 556.05% in 2022, then fell 9.42% in 2025.
  • A 5-year view of Operating Leases shows it stood at $6.1 million in 2021, then surged by 546.43% to $39.4 million in 2022, then dropped by 6.41% to $36.8 million in 2023, then dropped by 7.6% to $34.0 million in 2024, then fell by 9.42% to $30.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $30.8 million in Q4 2025, $31.7 million in Q3 2025, and $32.5 million in Q2 2025.